Compare ASUR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASUR | CRBP |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.4M | 184.4M |
| IPO Year | 1996 | 2014 |
| Metric | ASUR | CRBP |
|---|---|---|
| Price | $8.79 | $8.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $14.33 | ★ $45.50 |
| AVG Volume (30 Days) | 83.9K | ★ 671.5K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $88,952,000.00 | $4,822,272.00 |
| Revenue This Year | $16.33 | N/A |
| Revenue Next Year | $9.20 | $116.00 |
| P/E Ratio | $433.50 | ★ N/A |
| Revenue Growth | 63.39 | ★ 97.62 |
| 52 Week Low | $6.80 | $6.73 |
| 52 Week High | $11.47 | $20.56 |
| Indicator | ASUR | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 44.89 |
| Support Level | $7.91 | $7.62 |
| Resistance Level | $8.91 | $8.54 |
| Average True Range (ATR) | 0.38 | 0.58 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 17.36 | 38.19 |
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its products majorly in the United States.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.